Trends in the risk and benefits to patients with cancer participating in phase 1 clinical trials

JAMA

Volumn 292, Issue 17, 2004, Pages 2130-2140

  Roberts, Thomas G ^a,b,c   Goulart, Bernardo H ^b   Squitieri, Lee ^c   Stallings, Sarah C ^c   Halpern, Elkan F ^a   Chabner, Bruce A ^b   Gazelle, G Scott ^a   Finkelstein, Stan N ^c   Clark, Jeffrey W ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CETUXIMAB; DOCETAXEL; EXEMESTANE; GEFITINIB; GEMCITABINE; IRINOTECAN; PEMETREXED; RETINOIC ACID; TEMOZOLOMIDE; TOPOTECAN;

BRAIN DISEASE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; COMA; CONFIDENCE INTERVAL; COUGHING; DRUG FATALITY; DYSPNEA; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; KIDNEY FAILURE; LUNG CANCER; LUNG EMBOLISM; MORTALITY; NEPHROTIC SYNDROME; NEUROLOGIC DISEASE; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TIME SERIES ANALYSIS; ARTICLE; META ANALYSIS; NEOPLASM; PHASE 1 CLINICAL TRIAL; RISK; STATISTICS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; HUMANS; NEOPLASMS; RISK; TREATMENT OUTCOME;

EID: 7244243743     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.17.2130     Document Type: Review

References (44)

1. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95:1276-1299.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
3. Parexel's Pharmaceutical R&D Statistical Sourcebook 2003/2004. Waltham, Mass: Parexel International Corp; 2003.
4. Roberts TG Jr, Lynch TJ Jr, Chabner BA. The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. J Clin Oncol. 2003;21:3683-3695.
5. Daugherty C, Ratain MJ, Grochowski E, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995;13:1062-1072.
6. Meropol NJ, Weinfurt KP, Burnett CB, et al. Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol. 2003;21:2589-2596.
7. ClinicalTrials.gov Web site. Available at: http://www.clinicaltrials.gov/ . Accessed July 1, 2004.
8. Lipsett MB. On the nature and ethics of phase I clinical trials of cancer chemotherapies. JAMA. 1982;248:941-942.
9. Miller M. Phase I cancer trials: a collusion of misunderstanding. Hastings Cent Rep. 2000;30:34-43.
10. Cox K, Avis M. Ethical and practical problems of early anti-cancer drug trials: a review of the literature. Eur J Cancer Care (Engl). 1996;5:90-95.
11. Markman M. The ethical dilemma of phase I clinical trials. CA Cancer J Clin. 1986;36:367-369.
12. Emanuel EJ. A phase I trial on the ethics of phase I trials. J Clin Oncol. 1995;13:1049-1051.
13. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA. 2000;283:2701-2711.
14. Daugherty CK, Ratain MJ, Siegler M. Pushing the envelope: informed consent in phase I trials. Ann Oncol. 1995;6:321-323.
15. Daugherty CK. Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. J Clin Oncol. 1999;17:1601-1617.
16. Kodish E, Stocking C, Ratain MJ, Kohrman A, Siegler M. Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons. J Clin Oncol. 1992;10:1810-1816.
17. Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R. Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep. 1986;70:1105-1115.
18. Decoster G, Stein G, Holdener EE. Responses and toxic deaths in phase I clinical trials. Ann Oncol. 1990;1:175-181.
19. Von Hoff DD, Turner J. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs. 1991;9:115-122.
20. Smith TL, Lee JJ, Kantarjian HM, Legha SS, Raber MN. Design and results of phase I cancer clinical trials: three-year experience at M. D. Anderson Cancer Center. J Clin Oncol. 1996;14:287-295.
21. Cheng JD, Hitt J, Koczwara B, et al. Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol. 2000;18:421-428.
22. Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet. 2001;358:1772-1777.
23. Horng S, Emanuel EJ, Wilfond B, Rackoff J, Martz K, Grady C. Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med. 2002;347:2134-2140.
24. Agrawal M, Emanuel EJ. Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA. 2003;290:1075-1082.
25. Steinbrook R. Improving protection for research subjects. N Engl J Med. 2002;346:1425-1430.
26. Steinbrook R. Protecting research subjects - the crisis at Johns Hopkins. N Engl J Med. 2002;346:716-720.
27. Lorman AJ. Clinical trials face heightened scrutiny as science and commerce appear to merge. J Biolaw Bus. 2001;4:23-32.
28. American Society of Clinical Oncology. ASCO Annual Meetings. Available at: http://www.asco.org/ac /1,1003,_12-002092,00.asp. Accessed June 23, 2004.
29. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA. 2003;290:495-501.
30. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979. Publication No. 48.
31. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
32. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
33. National Cancer Institute Cancer Therapy Evalaution Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: http://ctep .cancer.gov/reporting/ctc.html. Accessed July 1, 2004.
34. Goldman L, Loscalzo A. Fate of cardiology research originally published in abstract form. N Engl J Med. 1980;303:255-259.
35. Chalmers I, Adams M, Dickersin K, et al. A cohort study of summary reports of controlled trials. JAMA. 1990;263:1401-1405.
36. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
37. Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer. 2003;39:55-61.
38. Johnson JR, Williams G, Pazdur R. End points and United States food and drug administration approval of oncology drugs. J Clin Oncol. 2003;21:1404-1411.
39. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 2001;19:265-272.
40. Daugherty CK, Siegler M, Ratain MJ, Zimmer G. Learning from our patients: one participant's impact on clinical trial research and informed consent. Ann Intern Med. 1997;126:892-897.
41. Edgar H, Rothman DJ. New rules for new drugs: the challenge of AIDS to the regulatory process. Milbank Q. 1990;68(suppl 1):111-142.
42. Wachter RM. AIDs, activism, and the politics of health. N Engl J Med. 1992;326:128-133.
43. Protection of Human Subjects, 45 CFR §46 (2001).
44. Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist. 2002;7:401-409.